Phathom Pharma Q3 net loss $51.1M, NERD trial enrollment complete

Phathom Pharmaceuticals, Inc.

2022-Q3 EPS reported -$3.72

Net loss of $51.1M in Q3 2022 vs. $36.7M in Q3 2021; R&D expense $19.0M, G&A $23.5M.
Cash and equivalents $196.8M at Sep 30, 2022; additional $100M available under term loan.
Completed enrollment in Phase 3 NERD daily dosing trial (776 patients); topline data expected Q1 2023.
Secured up to $40M additional non-dilutive financing under revenue interest agreement; total capacity $300M.
Planned Q1 2023 U.S. launches of VOQUEZNA TRIPLE PAK, DUAL PAK, and if approved, VOQUEZNA for EE.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Phathom Pharmaceuticals, Inc. reported the third quarter of 2022 results: net income Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter.

Period: the third quarter of 2022
Net income: Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter
Result: reported results

Exact text from the filing

On November 8, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-280741

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.